Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.
The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.
Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.
The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.
Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.
NanoString Technologies (NASDAQ:NSTG) announced that its CEO, Brad Gray, will present at two healthcare conferences. On August 10, he will participate in a spatial biology panel at the 42nd Annual Canaccord Global Growth Conference at 12:00 PM ET and a fireside chat at 2:30 PM ET. On August 11, Gray will join a fireside discussion at the UBS Genomics 2.0 and MedTech Innovation Conference at 10:00 AM PT. Live webcasts are accessible on the company’s investor website.
DermTech, Inc. (NASDAQ: DMTK) announced the appointment of Kirk D. Malloy, Ph.D., and Mark C. Capone, M.S., to its board of directors, effective July 18, 2022. This addition expands DermTech’s board to eight members. Both directors bring extensive experience in life sciences and business development, enhancing DermTech's strategic direction. Dr. Malloy has over 25 years in leadership roles at companies like Illumina, while Mr. Capone previously led Myriad Genetics, positioning DermTech for growth in precision dermatology.
NanoString Technologies (NASDAQ:NSTG) will report its second quarter 2022 operating results on August 4, 2022, after market close. Following the report, management will host a conference call at 4:30 PM ET to discuss results and provide updates. Interested investors can register for the call via their Investor Relations website. A replay of the call will be available from August 4, 2022, 7:30 PM ET, to August 11, 2022. NanoString specializes in life science tools, offering systems to profile gene expression and spatial analysis.
NanoString Technologies (NASDAQ: NSTG) has announced the launch of its AtoMx Spatial Informatics Portal (SIP) at the Spatial Multiomic Symposium during the AGBT General Meeting in Orlando, FL on June 6, 2022. This cloud-based platform integrates workflows for the GeoMx DSP and CosMx SMI systems, significantly reducing data processing time from days to hours and enhancing collaborative data sharing. AtoMx aims to revolutionize spatial biology data analysis, with the beta testing expected to lead to a commercial launch in Fall 2022.
NanoString Technologies (NSTG) announced the launch of its CosMx™ Spatial Molecular Imager (SMI) and a new spatial informatics portal at the upcoming Spatial Multiomic Symposium on June 6, from noon to 4 pm EDT. This event will showcase data from twenty scientific studies that emphasize the capabilities of NanoString's spatial biology platforms. CosMx SMI allows high-resolution imaging of over 1,000 RNA and 100 protein analytes within tissue sections. The company aims to propel advancements in life sciences through innovative spatial biology solutions.
NanoString Technologies, Inc. (NASDAQ: NSTG) has announced a new cloud-based workflow for spatial multiomic analysis that integrates with Illumina's NextSeq 1000 and 2000 systems. This innovation simplifies the process by allowing GeoMx users to plan sequencing runs and automate data processing through Illumina's DRAGEN platform. The workflow enhances the interaction, visualization, and analysis of multiomic data. This release is part of a broader partnership with Illumina, aimed at improving data analysis efficiency and enhancing user experience in life sciences.
NanoString Technologies (NASDAQ:NSTG) announced its participation in the 2022 UBS Global Healthcare Conference, with CEO Brad Gray presenting on May 25, 2022, at 9:15 am ET. The presentation will be accessible via webcast on the company's website, with a replay available for 60 days. NanoString is recognized for its life science tools, including the nCounter® Analysis System, utilized in over 5,250 peer-reviewed publications, and the GeoMx® Digital Spatial Profiler, cited in roughly 110 publications. The CosMx™ Spatial Molecular Imager is set for commercial availability in 2022.
NanoString Technologies, Inc. (NASDAQ:NSTG) reported Q1 2022 financial results with total product and service revenue at $30.8 million, slightly down from the previous year. GeoMx® DSP revenue decreased by 31% year-over-year, totaling $9.7 million, while consumables showed 78% growth. nCounter® revenue fell by 11%, with total service revenue at $4.3 million, a 16% increase. The company updated its 2022 outlook, now projecting revenue of $150-$160 million, down from previous estimates. Cash reserves stand at $312.1 million.
NanoString Technologies (NASDAQ:NSTG) will report its first quarter 2022 operating results on May 10, 2022, after market close. A conference call is scheduled for 4:30pm ET to discuss the results and provide business updates. Interested investors are encouraged to register in advance for the call, with details available on their investor relations website. A replay of the call will be accessible from 7:30pm ET on May 10 until midnight on May 17, 2022. NanoString is known for its innovative life science tools for research, including the nCounter® Analysis System and the GeoMx® Digital Spatial Profiler.
NanoString Technologies (NASDAQ: NSTG) announced the appointment of Dr. Teresa Foy to its Board of Directors, effective April 18, 2022, following Dr. Rob Hershberg's resignation after seven years. Dr. Foy, an expert in immuno-oncology and cellular therapy, brings over 25 years of experience from her roles at Bristol Myers Squibb and Celgene. CEO Brad Gray emphasized Dr. Foy's expertise in leveraging life science tools to drive drug development, particularly for cancer treatments. The company's innovative platforms, including the nCounter® Analysis System and GeoMx® Digital Spatial Profiler, enhance biological research capabilities.
FAQ
What is the market cap of NanoString Technologies (NSTG)?
What is NanoString Technologies' primary business?
What is the nCounter® Analysis System?
What are some applications of NanoString's technology?
Has NanoString been involved in any legal issues recently?
What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?
What is the significance of the nCounter Dx Analysis System?
How many peer-reviewed publications have cited the nCounter® system?
What is the cost advantage of NanoString's technology?
What are the legal implications of the injunctions against NanoString in Europe?
How does NanoString contribute to advancements in human health?
